Maria Gonzalez

4.4k citations

53 papers · 1.7k indexed · 1 hit paper · h-index 15

Oncology top 2%
Molecular Biology
Pulmonary and Respiratory Medicine top 5%
Immunology top 10%
Genetics top 5%

Co-authors: Georgina V. Long Alexander M. Menzies Serigne Lo Richard A. Scolyer Shahneen Sandhu Michael P. Brown Grant A. McArthur Alexander Guminski
Topics: Cancer Immunotherapy and Biomarkers (28 papers)CAR-T cell therapy research (18 papers)Cutaneous Melanoma Detection and Management (18 papers)
Cited by: Oncology Genetics Pulmonary and Respiratory Medicine
Journals: Cell Nature Medicine Journal of Clinical Oncology
Partner nations: Australia Netherlands Sweden

In The Last Decade

Maria Gonzalez

49 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

2018 655 citations Georgina V. Long, Victoria Atkinson et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Maria Gonzalez

Since Specialization

Citations

This map shows the geographic impact of Maria Gonzalez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Gonzalez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Gonzalez more than expected).

Fields of papers citing papers by Maria Gonzalez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Gonzalez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Gonzalez. The network helps show where Maria Gonzalez may publish in the future.

Co-authorship network of co-authors of Maria Gonzalez

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Gonzalez. A scholar is included among the top collaborators of Maria Gonzalez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Gonzalez. Maria Gonzalez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study 2025 ·The Lancet Oncology ·Georgina V. Long,Victoria Atkinson,Serigne Lo,Alexander Guminski,Shahneen Sandhu,Michael P. Brown,Maria Gonzalez,Grant A. McArthur,Alexander M Menzies	9
2	Tumor-infiltrating lymphocyte expansion protocols for adoptive cell therapy in cancer 2025 ·Cellular Oncology ·(unknown),(unknown),(unknown),(unknown),Maria Gonzalez,Miguel Fernández‐Arquero,Pedro Pérez Segura,(unknown),Silvia Sánchez‐Ramón,Alberto Ocaña,(unknown)	0
3	FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. 2024 ·Journal of Clinical Oncology ·Li Zhou,Edward Hsiao,Serigne Lo,Matteo S. Carlino,George Au‐Yeung,Maria Gonzalez,Andrew J. Spillane,Thomas E. Pennington,Julie R. Howle,Kerwin F. Shannon,Rony Kapoor,Jonathan R. Stretch,David Gyorki,Robyn P.M. Saw,Sydney Ch’ng,Richard A. Scolyer,Georgina V. Long,Alexander M. Menzies	0
4	A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Jason J. Luke,Laura C. Kennedy,(unknown),Alexander M. Menzies,Alexander Christopher Jonathan Van Akkooi,Maria Gonzalez,Julie Urban,(unknown),(unknown),(unknown),Brian J. Miller,(unknown),Ryan Sowell,Prashant R. Nambiar,Tasuku Kitada,Sarina A. Piha‐Paul,Kamalesh K. Sankhala,Georgina V. Long	3
5	Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma 2024 ·Annals of Oncology ·Alexander M. Menzies,Serigne Lo,Robyn P.M. Saw,Maria Gonzalez,Sydney Ch’ng,(unknown),Kerwin F. Shannon,(unknown),Jenny Lee,Louise Emmett,(unknown),(unknown),Jonathan R. Stretch,John F. Thompson,(unknown),Helen Rizos,(unknown),Georgina V. Long	8
6	Use of early circulating tumour DNA dynamics in patients with stage III melanoma receiving neoadjuvant combination immunotherapy. 2024 ·Journal of Clinical Oncology ·(unknown),Jenny Lee,Ashleigh Stewart,Russell J. Diefenbach,Maria Gonzalez,Alexander M. Menzies,Christian U. Blank,Richard A. Scolyer,Georgina V. Long,Helen Rizos	1
7	A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC). 2024 ·Journal of Clinical Oncology ·Maria Gonzalez,Alexander Christopher Jonathan Van Akkooi,Sydney Ch’ng,Kerwin F. Shannon,Andrew J. Spillane,Jonathan R. Stretch,(unknown),Thomas E. Pennington,(unknown),Robyn P.M. Saw,Rony Kapoor,Edward Hsiao,Robert V. Rawson,(unknown),Alexander M. Menzies,Serigne Lo,Richard A. Scolyer,Angela Hong,Georgina V. Long,(unknown)	0
8	Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial 2024 ·Nature Medicine ·Georgina V. Long,Matteo S. Carlino,George Au‐Yeung,Andrew J. Spillane,Kerwin F. Shannon,David Gyorki,Edward Hsiao,Rony Kapoor,(unknown),(unknown),Julie R. Howle,Sydney Ch’ng,Maria Gonzalez,Robyn P.M. Saw,Thomas E. Pennington,Serigne Lo,Richard A. Scolyer,Alexander M. Menzies	15
9	The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo. 2023 ·Journal of Clinical Oncology ·Irene L. M. Reijers,Alexander M. Menzies,Judith M. Versluis,Robyn P.M. Saw,Winan J. van Houdt,Ellen Kapiteijn,(unknown),Karijn P.M. Suijkerbuijk,Hanna Eriksson,Geke A.P. Hospers,W. Martin C. Klop,Marta López‐Yurda,Lindsay G. Grijpink-Ongering,Maria Gonzalez,Andrew J. Spillane,Richard A. Scolyer,Bart A. van de Wiel,Alexander Christopher Jonathan Van Akkooi,Georgina V. Long,Christian U. Blank	6
10	1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma 2023 ·Annals of Oncology ·(unknown),Elisa A. Rozeman,Judith M. Versluis,Alexander M. Menzies,Hanna Eriksson,B. van de Wiel,Richard A. Scolyer,(unknown),Henk Mallo,Maria Gonzalez,(unknown),(unknown),Lindsay G. Grijpink-Ongering,John B.A.G. Haanen,Alexander C. J. van Akkooi,Georgina V. Long,Christian U. Blank	1
11	Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma 2023 ·Nature Medicine ·(unknown),Irene L. M. Reijers,Petros Dimitriadis,Annegien Broeks,Maria Gonzalez,Alexander M. Menzies,Marta López‐Yurda,Ellen Kapiteijn,Astrid A.M. van der Veldt,Karijn P.M. Suijkerbuijk,Geke A.P. Hospers,Georgina V. Long,Christian U. Blank,Lonneke V. van de Poll‐Franse	22
12	793P NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma 2022 ·Annals of Oncology ·Georgina V. Long,Andrew J. Spillane,Thomas E. Pennington,Kerwin F. Shannon,Jonathan R. Stretch,Maria Gonzalez,(unknown),Serigne Lo,Richard A. Scolyer,Alexander M. Menzies	11
13	Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia 2019 ·Cancer Chemotherapy and Pharmacology ·Hannah Yejin Kim,Janna K. Duong,Maria Gonzalez,Georgina V. Long,Alexander M. Menzies,Helen Rizos,Su Yin Lim,Jenny Lee,Alan V. Boddy	15
14	Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy 2019 ·Cancer ·Inês Pires da Silva,Serigne Lo,Camelia Quek,Maria Gonzalez,Matteo S. Carlino,Georgina V. Long,Alexander M. Menzies	108
15	OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) 2018 ·Annals of Oncology ·Christian U. Blank,Elisa A. Rozeman,Alexander M. Menzies,Bart A. van de Wiel,Chandra Mani Adhikari,Karolina Sikorska,Oscar Krijgsman,Hanna Eriksson,Carolien Bierman,Lindsay G. Grijpink-Ongering,Maria Gonzalez,Annegien Broeks,Alexander Guminski,Andrew J. Spillane,W. Martin C. Klop,Robyn P.M. Saw,Richard A. Scolyer,Alexander C. J. van Akkooi,Johan Hansson,Georgina V. Long	12
16	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 studybreakdown → 2018 ·The Lancet Oncology ·Georgina V. Long,Victoria Atkinson,Serigne Lo,Shahneen Sandhu,Alexander Guminski,Michael P. Brown,James S. Wilmott,Jarem Edwards,Maria Gonzalez,Richard A. Scolyer,Alexander M. Menzies,Grant A. McArthur	655
17	A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D+T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial) 2017 ·Annals of Oncology ·Maria Gonzalez,Alexander M. Menzies,Robyn P.M. Saw,John F. Thompson,Andrew J. Spillane,Julie R. Howle,Omgo E. Nieweg,Kerwin F. Shannon,Sydney Ch’ng,Jonathan R. Stretch,Matteo S. Carlino,Alexander Guminski,Louise Emmett,Helen Rizos,Richard A. Scolyer,Georgina V. Long	7
18	Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma 2017 ·Annals of Oncology ·Alexander M. Menzies,Maria Gonzalez,Alex Guminski,Omgo E. Nieweg,Kerwin F. Shannon,John F. Thompson,Richard Kefford,Sydney Ch’ng,Jonathan R. Stretch,Andrew J. Spillane,(unknown),(unknown),Rony Kapoor,Louise Emmett,Helen Rizos,Robyn P.M. Saw,Richard A. Scolyer,Georgina V. Long	29
19	Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma. 2016 ·Journal of Clinical Oncology ·Robyn P.M. Saw,Alexander M. Menzies,Alexander Guminski,Omgo E. Nieweg,Kerwin F. Shannon,Maria Gonzalez,Sydney Ch’ng,Richard Kefford,John F. Thompson,Jonathan R. Stretch,Andrew J. Spillane,Richard A. Scolyer,Georgina V. Long	7
20	Phase III randomized pilot study comparing interferon alpha- 2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix 2003 ·International Journal of Gynecological Cancer ·R Yazigi,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Rodrigo L. Castillo,Begoña Cerdá,Miguel A. Cumsille,Maria Gonzalez,(unknown),Jose Reyes	10

About Maria Gonzalez

Maria Gonzalez is a scholar working on Oncology, Biological Psychiatry and Molecular Biology, having authored 53 papers that have together received 1.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (28 papers), CAR-T cell therapy research (18 papers) and Cutaneous Melanoma Detection and Management (18 papers). The work is most often cited by research in Oncology (1.1k citations), Genetics (233 citations) and Pulmonary and Respiratory Medicine (544 citations). Maria Gonzalez has collaborated with scholars based in Australia, Netherlands and Sweden. Frequent co-authors include Georgina V. Long, Alexander M. Menzies, Serigne Lo, Richard A. Scolyer, Shahneen Sandhu, Michael P. Brown, Grant A. McArthur, Alexander Guminski, Victoria Atkinson and Jarem Edwards. Their work appears in journals such as Cell, Nature Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact